Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference

Rhea-AI Summary

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) announced participation in the Canaccord Genuity 40th Annual Growth Conference from August 11-13, 2020. Key executives, including Dr. William G. Rice, will present a corporate overview and strategic direction on August 13 at 2:00 p.m. ET. The live presentation can be accessed via Webcast Link, with an archived version available for 90 days on the company's website.

SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer; Gregory K. Chow, Executive Vice President and Chief Financial Officer; and Joti Marango, M.D., Ph.D, Senior Vice President and Chief Business Officer, will participate in the Canaccord Genuity 40^th Annual Growth Conference being held in a virtual format from Tuesday, August 11^th to Thursday, August 13^th, 2020. 

Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction:

Aptose Fireside Chat

Time:     2:00 p.m. ET
Date:     Thursday, August 13, 2020

A live webcast of the Aptose presentation will be accessible by visiting the following link:

Webcast Link

The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com

About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and has received an IND allowance to conduct a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).

For further information, please contact:
Aptose Biosciences Inc.				LifeSci Advisors, LLC
Greg Chow				Dan Ferry, Managing Director
Executive Vice President, CFO				617-535-7746
858-926-2730				Daniel@LifeSciAdvisors.com
gchow@aptose.com
SMP Communications
Susan Pietropaolo
201-923-2049
susan@smpcommunications.com

FAQ

What event will Aptose Biosciences participate in on August 11-13, 2020?

Aptose Biosciences will participate in the Canaccord Genuity 40th Annual Growth Conference.

Who will present at the Canaccord Genuity Conference for Aptose?

Dr. William G. Rice and other key executives will present at the conference.

When is the Aptose Fireside Chat scheduled?

The Aptose Fireside Chat is scheduled for August 13, 2020, at 2:00 p.m. ET.

How can I access the Aptose presentation live?

The live presentation can be accessed via the provided webcast link.

Will the Aptose presentation be available after the live event?

Yes, the webcast will be archived and available for 90 days on the Aptose website.